Anti-obesity drugs are closing the gap between dieting and bariatric surgery | Diet and Nutrition
The emergence of a new GLP-1 drug called pemvidutide, developed by Altimmune, presents a promising advancement in the realm of weight-loss medications. Unlike existing GLP-1 drugs like Ozempic and Wegovy, which may lead to significant muscle loss along with fat reduction, pemvidutide aims to preserve muscle mass while targeting fat loss.
In a Phase II clinical trial, pemvidutide demonstrated its ability to help patients shed approximately 75% fat while retaining 25% muscle, a notable improvement compared to other GLP-1 drugs. This balance between fat reduction and muscle preservation is crucial for the overall health and well-being of patients, particularly vulnerable populations like older adults.
The mechanism behind pemvidutide’s muscle-sparing effect involves combining a GLP-1 drug with glucagon, a hormone responsible for regulating blood sugar levels. While the GLP-1 component decreases appetite, the glucagon element is believed to simulate the effects of exercise, thereby potentially mimicking the benefits of strength training without the actual physical exertion.
Altimmune’s Chief Medical Officer, Scott Harris, emphasized the importance of focusing not only on the quantity but also the quality of weight loss. If approved, pemvidutide could offer a compelling option for individuals seeking effective weight loss and maintenance strategies.
In addition to Altimmune, other pharmaceutical companies like Eli Lilly are exploring solutions to mitigate muscle loss associated with GLP-1 drugs. Eli Lilly’s acquisition of Versanis, a company developing a muscle-preserving monoclonal antibody called bimagrumab, highlights the industry’s efforts to address this concern. Clinical trials combining bimagrumab with semaglutide, the active ingredient in Ozempic, signify ongoing endeavors to improve the overall safety and efficacy profile of weight-loss medications.
#WeightLoss #MusclePreservation #Pemvidutide #GLP1 #HealthyLiving